Study of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2024 According to an Unravel Biosciences media release, initiation of patient dosing for the RVL-001 trial in RTT and extension trial in PTHS are both anticipated in early 2025.
14 Jun 2024 New trial record
11 Jun 2024 According to an Unravel Biosciences media release, the company announced a collaboration to conduct a proof of concept clinical trial of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS).Under the terms of the collaboration, the Foundation will fund the clinical trial conducted by Unravel at its study site in Colombia and Unravel will retain rights for further development and commercialization.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com